Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure [5]

Kidney International

Volumn 69, Issue 6, 2006, Pages 1094-

  Courtney, A E ^a   Doherty, C C ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TAMOXIFEN;

CATHETER REMOVAL; EXPERIENCE; HIGH RISK PATIENT; IMMUNE RESPONSE; KIDNEY FAILURE; LETTER; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCLEROSIS;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; CATHETERIZATION; CHRONIC DISEASE; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONITIS; SCLEROSIS;

EID: 33644852243     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000217     Document Type: Letter

References (4)

1. Summers AM, Clancy MJ, Syed F et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68: 2381-2388.
2. Courtney AE, Doherty CC. Fulminant sclerosing peritonitis immediately following acute bacterial peritonitis. Nephrol Dial Transplant 2006; 21: 532-534.
3. Rajani R, Smyth J, Koffman CG et al. Differential effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant 2002; 17: 2278-2280.
4. Kawanishi H, Kawaguchi Y, Fukui H et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44: 729-737.